BR112017001474A2 - mutações no domínio extracelular iii do gene receptor de fator de crescimento epidérmico - Google Patents

mutações no domínio extracelular iii do gene receptor de fator de crescimento epidérmico

Info

Publication number
BR112017001474A2
BR112017001474A2 BR112017001474A BR112017001474A BR112017001474A2 BR 112017001474 A2 BR112017001474 A2 BR 112017001474A2 BR 112017001474 A BR112017001474 A BR 112017001474A BR 112017001474 A BR112017001474 A BR 112017001474A BR 112017001474 A2 BR112017001474 A2 BR 112017001474A2
Authority
BR
Brazil
Prior art keywords
mutations
growth factor
factor receptor
epidermal growth
receptor gene
Prior art date
Application number
BR112017001474A
Other languages
English (en)
Inventor
Dalmases Massegú Alba
Bardelli Alberto
Rovira Guerin Ana
Bellosillo Paricio Beatriz
Montagut Viladot Clara
Albanell Mestres Joan
Arena Sabrina
Original Assignee
Bardelli Alberto
Fundacio Inst Mar D´Investigacions Mediques Imim
Arena Sabrina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bardelli Alberto, Fundacio Inst Mar D´Investigacions Mediques Imim, Arena Sabrina filed Critical Bardelli Alberto
Publication of BR112017001474A2 publication Critical patent/BR112017001474A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo ?mutações no domínio extracelular iii do gene receptor de fator de crescimento epidérmico? a invenção refere-se às novas mutações identificadas no gene receptor de fator de crescimento epidérmico, conduzindo as alterações de aminoácido que altamente correlacionam com a resistência a um regime terapêutico compreendendo cetuximabe. a invenção inclui sequências peptídicas e iniciadores para detectar as mutações, assim como kits para prognosticar a resposta de um sujeito a um regime terapêutico compreendendo cetuximabe. em particular, a invenção é útil no regime terapêutico aplicável para câncer colorretal metastático.
BR112017001474A 2014-07-28 2014-12-30 mutações no domínio extracelular iii do gene receptor de fator de crescimento epidérmico BR112017001474A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382288 2014-07-28
PCT/EP2014/079477 WO2016015788A1 (en) 2014-07-28 2014-12-30 Mutations in the extracellular domain iii of epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
BR112017001474A2 true BR112017001474A2 (pt) 2018-02-20

Family

ID=51225482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001474A BR112017001474A2 (pt) 2014-07-28 2014-12-30 mutações no domínio extracelular iii do gene receptor de fator de crescimento epidérmico

Country Status (8)

Country Link
US (2) US11015225B2 (pt)
EP (2) EP3174896B1 (pt)
JP (1) JP6905464B2 (pt)
CN (1) CN106573967B (pt)
BR (1) BR112017001474A2 (pt)
CA (1) CA2954952C (pt)
ES (1) ES2693080T3 (pt)
WO (1) WO2016015788A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982287B2 (en) * 2015-01-06 2021-04-20 The Johns Hopkins University Response to EGFR blockade
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用
CN115947823B (zh) * 2022-09-29 2024-05-03 江汉大学 一种用于筛选结合和/或激活egfr的有毒金属的表达蛋白及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914269A (en) * 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
WO2005094357A2 (en) * 2004-03-31 2005-10-13 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
CN103890245B (zh) * 2011-05-20 2020-11-17 富鲁达公司 核酸编码反应
EP2554551A1 (en) 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene

Also Published As

Publication number Publication date
CA2954952C (en) 2023-05-23
WO2016015788A1 (en) 2016-02-04
EP3428185A1 (en) 2019-01-16
EP3174896A1 (en) 2017-06-07
CN106573967A (zh) 2017-04-19
CA2954952A1 (en) 2016-02-04
US20170260250A1 (en) 2017-09-14
ES2693080T3 (es) 2018-12-07
JP2017522890A (ja) 2017-08-17
CN106573967B (zh) 2022-02-18
JP6905464B2 (ja) 2021-07-21
US11015225B2 (en) 2021-05-25
EP3174896B1 (en) 2018-08-22
US20210262037A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
IL251274A0 (en) Detection of target sequences using nanochannel sensors of synthetic detectors
CL2016001868A1 (es) Proteinas de union y sus métodos de uso
UY35385A (es) ?métodos y composiciones para el control de malezas?.
TWD189837S (zh) 定序儀之前面板
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
EP3169224A4 (en) Systems for sensing, measuring and characterizing compliance and/or elastic changes of vessels or lesions
ECSP13013022A (es) Agonistas de fgfr1 y sus métodos de uso
AR095232A1 (es) Métodos y composiciones para el control de malezas
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
NI201500099A (es) Inhibidores de erk y sus usos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
BR112017002270A2 (pt) aptâmero, uso de um aptâmero, composição farmacêutica, coluna de aférese e método para a preparação de um oligonucleotídeo aptâmero
BR112014000443A2 (pt) métodos e ácidos nucléicos para determinação do prognóstico de um indivíduo com câncer
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
SI3200582T1 (sl) Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov
MX2014016036A (es) Sistemas, metodos y equipo para determinar la presencia de fluidos de interes.
BR112014002373A2 (pt) mutações no gene do receptor do fator de crescimento epidermal
EP3206689A4 (en) Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
CO2018000194A2 (es) Alelos de dominio mads-box para controlar el fenotipo de membrana en la palma
EP3198063A4 (en) Rna stitch sequencing: an assay for direct mapping of rna : rna interactions in cells
DK3207052T3 (da) Biosensor baseret på gbetagamma-interagerende proteiner til at monitorere g-proteinaktivering

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]